May 18Thursday, 18 May 2023 - MT (Mexican Pacific Time, GMT-07:00)

• Get insight into new data on how two pipeline ADCs targeting acute myeloid lymphoma and pancreatic cancer have performed
• Partner to bring the next generation of ADCs to market

• Partner with the largest biomedical research center in the world
• Six business opportunities to bolster your pipeline and bottom line
• Business and financial advantages of working with a Federal Lab

• Get expert insight into the potential and current limitations of antigen-drug conjugates
• Partner with the next wave of targeted oncology therapeutics
• Understand why big pharma are so interested by having a conversation with an expert strategist

• Hear from the upcoming companies in the immuno-oncology space who have enhanced their therapeutics to overcome the current limitations of immuno-oncology
• Invest to make history and be apart of the team who makes immuno-oncology succeed

Make the most of your digital experience and utilise our platform during the break:

• Organize 1-2-1 meetings with fellow attendees with the option to video chat
• Expand your network and talk with the experts of women's health
• Ask speakers about their presentations

• Hear from Astellas on what makes partnership excellence
• Insight into the strategic models that enable win-win partnerships and successful results
• Join an industry recognised partner, take a focused area approach and develop a marketable ADC
• Review of the newest partnerships in the ADC space
• Case studies on collaborations between Astellas, Seagen and Sutro
• Converse with business development leaders who made the deal happen
• Learn from all perspectives on how to strike the perfect partnership deal

• Enjoy the unique opportunity to partner with the advanced next generation of drug conjugates; peptide drug conjugates
• Directly engage with an expert veteran in co-development partnerships and understand the pitfalls and challenges when partnering
• Insight into the ground-breaking science of a new targeted delivery platform that could see effective delivery of therapeutic payloads

• Hear about Zenocutuzumab (Zeno), the first therapeutic targeting NRG1+ fusions
• Hear directly from the CSO
• Pre-clinical and clinical data presented

Make the most of your digital experience and utilise our platform during the break:

• Organize 1-2-1 meetings with fellow attendees with the option to video chat
• Expand your network and talk with the experts of women's health
• Ask speakers about their presentations

• Here from an individual working on multiple boards of innovative oncology companies to get expert advice
• Partner to be only the second drug targeting KRAS on the market

• Insight into a new innovative technology making drug characterization more straight forward than ever
• Accurately predict your drugs primary target, effectiveness against wild-type and mutant forms, and potential secondary targets
• Accelerate drug prioritization and target discovery
• Boost your clinical success and FDA applications by partnering with the National Institute of Health

• Hear the gripping story of a cancer patient
• Put the human into this conference
• Get back to the basic of why we are here and what the true aim of collaboration is.